|
Video: What is a Stock Split?
|
|
ChemoCentryx is an integrated biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. Co. targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the U.S., Co. markets TAVNEOS® (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis), specifically granulomatosis with polyangiitis, and microscopic polyangiitis. Co. is also developing TAVNEOS for the treatment of severe Hidradenitis Suppurativa. According to our CCXI stock split history records, CCXI has had 0 splits. | |
|
CCXI (CCXI) has 0 splits in our CCXI stock split history database.
Looking at the CCXI stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into CCXI shares, starting with a $10,000 purchase of CCXI, presented on a split-history-adjusted basis factoring in the complete CCXI stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/01/2014 |
|
End date: |
10/20/2022 |
|
Start price/share: |
$6.87 |
|
End price/share: |
$51.99 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
656.77% |
|
Average Annual Total Return: |
26.68% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$75,695.21 |
|
Years: |
8.56 |
|
|
|
|
|